Navigation Links
New research confirms efficacy of transcranial magnetic stimulation for depression

PROVIDENCE, R.I. In one of the first studies to look at transcranial magnetic stimulation (TMS) in real-world clinical practice settings, researchers at Butler Hospital, along with colleagues across the U.S., confirmed that TMS is an effective treatment for patients with depression who are unable to find symptom relief through antidepressant medications. The study findings are published online in the June 11, 2012 edition of Depression and Anxiety in the Wiley Online Library.

Previous analysis of the efficacy of TMS has been provided through more than 30 published trials, yielding generally consistent results supporting the use of TMS to treat depression when medications aren't sufficient. "Those previous studies were key in laying the groundwork for the FDA to approve the first device for delivery of TMS as a treatment for depression in 2008," said Linda Carpenter, MD, lead author of the report and chief of the Mood Disorders Program and the Neuromodulation Clinic at Butler Hospital. "Naturalistic studies like ours, which provide scrutiny of real-life patient outcomes when TMS therapy is given in actual clinical practice settings, are the next step in further understanding the effectiveness of TMS. They are also important for informing healthcare policy, particularly in an era when difficult decisions must be made about allocation of scarce resources."

Carpenter explains that naturalistic studies differ from controlled clinical trials because they permit the inclusion of subjects with a wider range of symptomatology and comorbidity, whereas controlled clinical trials typically have more rigid criteria for inclusion. "As a multisite study collecting naturalistic outcomes from patients in clinics in various regions in the U.S., we were also able to capture effects that might arise from introducing a novel psychiatric treatment modality like TMS in non-research settings," said Carpenter. In all, the study confirms how well TMS works in diverse settings where TMS is administered to a real-life population of patients with depression that have not found relief through many other available treatments.

The published report summarized data collected from 42 clinical TMS practice sites in the US, and included outcomes from 307 patients with Major Depressive Disorder (MDD) who had persistent symptoms despite the use of antidepressant medication. Change during TMS was assessed using both clinicians' ratings of overall depression severity and scores on patient self-report depression scales, which require the patient to rate the severity of each symptom on the same standardized scale at the end of each 2-week period. Rates for "response" and "remission" to TMS were calculated based on the same cut-off scores and conventions used for other clinical trials of antidepressant treatments. Fifty-eight percent positive response rate to TMS and 37 percent remission rate were observed.

"The patient outcomes we found in this study demonstrated a response rate similar to controlled clinical trial populations," said Dr. Carpenter, explaining that this new data validates TMS efficacy in treating depression for those who have failed to benefit from antidepressant medications. "Continued research and confirmation of the effectiveness of TMS is important for understanding its place in everyday psychiatric care and to support advocacy for insurance coverage of the treatment." Thanks in part to the advocacy efforts of Dr. Carpenter, TMS was recently approved for coverage by Medicare in New England, and it is also now covered by BCBSRI. "Next steps for TMS research involve enhancing our understanding of how to maintain positive response to TMS over time after the course of therapy ends and learning how to customize the treatment for patients using newer technologies, so TMS can help even more patients."


Contact: Holly Brown-Ayers
Women & Infants Hospital

Related medicine news :

1. Research links sexual imagery and consumer impatience
2. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
3. SFU duos protein discovery links to cancer research
4. Ageless education: Researchers create guide for intergenerational classrooms at nursing homes
5. Miriam researchers urge physicians to ask younger men about erectile dysfunction symptoms
6. ASH launches multi-million-dollar grant program to support critical blood disease research
7. New research seeks to improve survival for myeloma and lymphoma patients
8. Adolescent sexual behavior tied to motion picture sexual content exposure, says MU researcher
9. John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
10. Mount Sinai researchers discover new target for vaccine development in abundant immune cells
11. Researchers study vaccine as potential weapon against aggressive brain tumors
Post Your Comments:
Related Image:
New research confirms efficacy of transcranial magnetic stimulation for depression
(Date:11/30/2015)... ... November 30, 2015 , ... ... Center is one of a select few plastic surgeons in the New York ... removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat loss ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... TransPack Volume ... X . Choose from scrolling web-styled transitions to wipes with blur & drop ... direction and more. Seamlessly transition from one clip to the next with TransPack's ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
(Date:11/30/2015)... ... 30, 2015 , ... CTI Group (Holdings) Inc. (OTC:CTIG), a ... communication analytics, announced today that their Proteus® VoIP QMS solution now supports Skype ... Proteus® VoIP QMS (Quality Management System) does this by collecting the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 NHS Supply ... 20 TrueBeam™ machines from Varian Medical Systems (NYSE: ... program to replace older machines and institute modern ... UK,s public hospitals. The order, placed in September, ... licenses for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
Breaking Medicine Technology: